Last reviewed · How we verify
metformin and rosiglitazone
metformin and rosiglitazone is a Antidiabetic combination (biguanide + thiazolidinedione) Small molecule drug developed by New York Medical College. It is currently FDA-approved for Type 2 diabetes mellitus. Also known as: glucophage, avandia, avandamet.
This combination reduces blood glucose by decreasing hepatic glucose production (metformin) and improving insulin sensitivity in peripheral tissues (rosiglitazone).
This combination reduces blood glucose by decreasing hepatic glucose production (metformin) and improving insulin sensitivity in peripheral tissues (rosiglitazone). Used for Type 2 diabetes mellitus.
At a glance
| Generic name | metformin and rosiglitazone |
|---|---|
| Also known as | glucophage, avandia, avandamet |
| Sponsor | New York Medical College |
| Drug class | Antidiabetic combination (biguanide + thiazolidinedione) |
| Target | AMPK (metformin); PPAR-γ (rosiglitazone) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Metformin is a biguanide that inhibits hepatic gluconeogenesis and improves peripheral glucose uptake. Rosiglitazone is a thiazolidinedione that activates peroxisome proliferator-activated receptor gamma (PPAR-γ), enhancing insulin sensitivity in muscle and adipose tissue. Together, they address multiple pathophysiologic defects in type 2 diabetes.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Gastrointestinal disturbance (metformin-related)
- Weight gain (rosiglitazone-related)
- Fluid retention and edema
- Lactic acidosis (rare, metformin-related)
Key clinical trials
- Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study
- Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies (PHASE2)
- Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh (PHASE4)
- Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) (PHASE3)
- Effect of Metformin and Rosiglitazone Over no Diabetic With Metabolic Syndrome Patients. (PHASE2, PHASE3)
- Effects of Fatty Acid Delivery on Heart Metabolism and Function in Type 2 Diabetes (T2DM (NA)
- Study In Postmenopausal Women With Type 2 Diabetes Looking At Approved Diabetes Drugs And How They Affect Bone Health (PHASE4)
- Efficacy and Safety Study of Rosiglitazone/Metformin Therapy vs Rosiglitazone and Metformin in Type 2 Diabetes Subjects (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- metformin and rosiglitazone CI brief — competitive landscape report
- metformin and rosiglitazone updates RSS · CI watch RSS
- New York Medical College portfolio CI
Frequently asked questions about metformin and rosiglitazone
What is metformin and rosiglitazone?
How does metformin and rosiglitazone work?
What is metformin and rosiglitazone used for?
Who makes metformin and rosiglitazone?
Is metformin and rosiglitazone also known as anything else?
What drug class is metformin and rosiglitazone in?
What development phase is metformin and rosiglitazone in?
What are the side effects of metformin and rosiglitazone?
What does metformin and rosiglitazone target?
Related
- Drug class: All Antidiabetic combination (biguanide + thiazolidinedione) drugs
- Target: All drugs targeting AMPK (metformin); PPAR-γ (rosiglitazone)
- Manufacturer: New York Medical College — full pipeline
- Therapeutic area: All drugs in Diabetes
- Indication: Drugs for Type 2 diabetes mellitus
- Also known as: glucophage, avandia, avandamet
- Compare: metformin and rosiglitazone vs similar drugs
- Pricing: metformin and rosiglitazone cost, discount & access